Intranasal midazolam as first-line inhospital treatment for status epilepticus: a pharmaco-EEG cohort study.

Lara KayNina MerkelAnemone von BlombergLaurent M WillemsSebastian BauerPhilipp S ReifSusanne Schubert-Bast Felix Rosenow Adam Strzelczyk

Published in: Annals of clinical and translational neurology (2019)

This pharmaco-EEG-based study showed that in-MDZ is effective and well-tolerated for the acute treatment of SE. EEG and clinical effects of in-MDZ administration occurred within 04:07 and 5:05 on average. Intranasal midazolam appears to be an easily applicable and rapidly effective alternative to buccal or intramuscular application as first-line treatment if an intravenous route is not available.

Keyphrases

functional connectivity
working memory
resting state
high dose
combination therapy
high density
acute respiratory distress syndrome
mechanical ventilation